Cargando…

Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation

OBJECTIVES: Chronic hepatitis C virus (HCV) is a leading cause of hospitalization and death in populations coinfected with human immunodeficiency virus (HIV). Sofosbuvir (SOF) is a pan-genotypic drug that should be combined with other agents as an oral treatment for HCV. We performed a 5-year horizo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cenderello, Giovanni, Artioli, Stefania, Viscoli, Claudio, Pasa, Ambra, Giacomini, Mauro, Giannini, Barbara, Dentone, Chiara, Nicolini, Laura Ambra, Cassola, Giovanni, Di Biagio, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706121/ https://www.ncbi.nlm.nih.gov/pubmed/26770065 http://dx.doi.org/10.2147/CEOR.S93641

Ejemplares similares

Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature
por: Mirabella, Michele, et al.
Publicado: (2018)

A comparison of inpatient admissions in 2012 from two European countries
por: Tittle, Victoria, et al.
Publicado: (2014)

Varied spectrum of clinical presentation and mortality in a prospective registry of visceral leishmaniasis in a low endemicity area of Northern Italy
por: Cenderello, Giovanni, et al.
Publicado: (2013)

Ten Years of Medical Informatics and Standards Support for Clinical Research in an Infectious Diseases Network
por: Mora, Sara, et al.
Publicado: (2023)

Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis
por: Cenderello, Giovanni, et al.
Publicado: (2017)

Quality of life of people living with HIV, preliminary results from IANUA (Investigation on Antiretroviral Therapy) study
por: Venturini, Alberto, et al.
Publicado: (2014)

Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?
por: Di Biagio, Antonio, et al.
Publicado: (2017)

Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing
por: Riccardi, Niccolò, et al.
Publicado: (2018)

Bloodstream infections in patients living with HIV in the modern cART era
por: Taramasso, L., et al.
Publicado: (2019)

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
por: Luetkemeyer, Anne F., et al.
Publicado: (2016)

The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy
por: Hussein, N.R.
Publicado: (2017)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL
por: Dentone, Chiara, et al.
Publicado: (2014)

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience
por: Tsai, Wei-Lun, et al.
Publicado: (2020)

Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
por: Pinchera, Biagio, et al.
Publicado: (2023)

A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals
por: Nicolini, Laura Ambra, et al.
Publicado: (2019)

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort
por: Nicolini, Laura Ambra, et al.
Publicado: (2023)

How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy
por: Taramasso, Lucia, et al.
Publicado: (2018)

Sofosbuvir, a Significant Paradigm Change in HCV Treatment
por: McQuaid, Thomas, et al.
Publicado: (2015)

HCV treatment in children and young adults with HIV/HCV co-infection in Europe
por: Turkova, Anna, et al.
Publicado: (2015)

Treatment of HCV NS3/4a Protease Inhibitor Experienced Patients with Sofosbuvir Containing Regimens in an Outpatient Clinic
por: Gilroy, Shelley, et al.
Publicado: (2017)

Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
por: Mazzitelli, Maria, et al.
Publicado: (2018)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
por: Huhn, Gregory D., et al.
Publicado: (2020)

Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
por: Banga, Jaspreet, et al.
Publicado: (2020)

Managing HCV/HIV coinfection
por: Danish, Fazal A., et al.
Publicado: (2009)

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

The Ligurian Human Immunodeficiency Virus Clinical Network: A Web Tool to Manage Patients With Human Immunodeficiency Virus in Primary Care and Multicenter Clinical Trials
por: Fraccaro, Paolo, et al.
Publicado: (2013)

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis
por: Mariantonietta, Pisaturo, et al.
Publicado: (2019)

A simple, feasible, efficient and safe treatment strategy of sofosbuvir/velpatasvir for chronic HCV/HIV-1 coinfected patients regardless of HCV genotypes: a multicenter, open-label study in China
por: Lin, Weiyin, et al.
Publicado: (2023)

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort
por: Lacombe, Karine, et al.
Publicado: (2017)

Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”
por: Nicolini, Laura Ambra, et al.
Publicado: (2020)

Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
por: Kayali, Zeid, et al.
Publicado: (2014)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report
por: Piekarska, Anna, et al.
Publicado: (2020)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gvgku9p9rued22d8809h6a7gnv